chrisvoncsefalvay/vaers-outcomes huggingface dataset:
This spontaneous report as received from a registered nurse refers to an unspecified number of patients of unknown age. Since 21-JUL-2014, the unspecified patients were vaccinated with doses of VARIVAX (lot #, dose, frequency unspecified) that were exposed to a temperature excursion. No adverse effect had been observed or reported. Additional information has been requested.
I woke up on March 9th, 2021, and my left eye was swollen shut and my right eye was partially swollen.  I am not an alarmist and I thought I was having an allergy reaction to food or the enviroment.  It occurred to me that this may be a response to the Moderna vaccination.  I did some research and discovered an adverse response is facial swelling and there was a photo of my exact adverse response.  It has not gone away is today it has gotten worse.  I went to the Clinic this morning.  I did call Moderna and report this the last week in March.  My second shot was scheduled for Monday, April 5th  and I was hesitant to take the shot when I was still exhibiting an adverse response.   I am starting to really be concerned as this has now started to go down into my entire face.   It is extremely uncomfortable and very itchy.  Never mind it is very unattractive -my swollen, red, and itchy eyes and now entire face.  At this time it is impossible to know if this is a permanent condition.  It has been 6 weeks and starting the 7th week with worsening coniditon.
Pt was vaccinated on right arm for pneumovax (Mecrk) and left arm for FLUARIX on 10/25/06. She presented to clinic on 1/4/07 c/o right shoulder pain that she claimed to have persisted since date of immunization. She subsequently followed up with her physician for imaging/xrays. She is now attending physical therapy for the arm as ordered by her physician, she reports.
Day 1, mild soreness in vaccinated arm. 4 days after the vaccination, strong vertigo.
sick in the stomach and throwing up; sick in the stomach and throwing up; Soreness in the arm of injection; This spontaneous case was reported by a consumer and describes the occurrence of ILLNESS (sick in the stomach and throwing up), VOMITING (sick in the stomach and throwing up) and VACCINATION SITE PAIN (Soreness in the arm of injection) in a 74-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 011m20a) for COVID-19 vaccination.     Concurrent medical conditions included Hypertension. Concomitant products included CALCIUM and COLECALCIFEROL (VIT D [COLECALCIFEROL]) for an unknown indication.    On 05-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 05-Feb-2021, the patient experienced ILLNESS (sick in the stomach and throwing up) (seriousness criterion medically significant), VOMITING (sick in the stomach and throwing up) (seriousness criterion medically significant) and VACCINATION SITE PAIN (Soreness in the arm of injection) (seriousness criterion medically significant). On 05-Feb-2021, ILLNESS (sick in the stomach and throwing up), VOMITING (sick in the stomach and throwing up) and VACCINATION SITE PAIN (Soreness in the arm of injection) had resolved.        mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosing remained unchanged.       Concomitant medications also included were hypertensive medications 1 pill a day and statin at night from an unknown date. Treatment information was not provided by the reporter.  Company Comment: Based on the current available information and temporal association between the use of the product and the start date of the events, a causal relationship cannot be excluded. Events were classified as serious by regulatory authority (seriousness criteria: medically important condition). However, as per medical criteria none of the events was serious (not IME listed and resolved).   This case was linked to MOD-2021-237390 (Patient Link).; Sender's Comments: Based on the current available information and temporal association between the use of the product and the start date of the events, a causal relationship cannot be excluded. Events were classified as serious by regulatory authority (seriousness criteria: medically important condition). However, as per medical criteria none of the events was serious (not IME listed and resolved).
pt recvd vax;GI upset;c/o pain,fever;no n,v,d,ha;;possible viral;
Patient presented to ED with chest pain radiating to the back, as well as left arm numbness, and lightheadedness. Patient was placed in observation unit - serial troponin negative, CTA showed no PE, mild ectasia of the distal ascending thoracic aorta. She was advised to follow up with PCP and cardiology for outpatient stress test. Per the EUA, hospitalizations are to be reported irrespective of attribution to the vaccine
Large local reaction on both thighs, 3-5 cm erythematous raised  plaque
Information has been received from an office manager concerning an approximately 48 year old female patient who in "before 2008" on an unspecified date, was vaccinated with one dose of VARIVAX (Merck) (Lot number not reported) at her practice. The office manager stated that the patient now presented to the physician with a rash suspicious of chicken pox. The patient had a blood test for antibodies to varicella zoster virus performed, that showed IgG title positive and IgM title negative. At the time of the report, patient had not recovered. Additional information has been requested.
Condition aggravated; Nausea; Vomiting; diarrhea; Headache; Weakness; Tiredness; This spontaneous case was reported by a non-health professional (subsequently medically confirmed) and describes the occurrence of CONDITION AGGRAVATED (Condition aggravated), DIARRHOEA (diarrhea), HEADACHE (Headache), ASTHENIA (Weakness) and FATIGUE (Tiredness) in a 49-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 026L20A and 030M20A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     The patient's past medical history included No Adverse Event (No medical history reported). Concomitant products included GALCANEZUMAB (EMGALITY [GALCANEZUMAB]), RIZATRIPTAN BENZOATE (MAXALT), ESTRADIOL and BUPROPION HYDROCHLORIDE (WELLBUTRIN) for an unknown indication.   On 09-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 10-Mar-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 10-Mar-2021, the patient experienced HEADACHE (Headache), ASTHENIA (Weakness) and FATIGUE (Tiredness). On 11-Mar-2021, the patient experienced DIARRHOEA (diarrhea). On 12-Mar-2021, the patient experienced CONDITION AGGRAVATED (Condition aggravated), NAUSEA (Nausea) and VOMITING (Vomiting). At the time of the report, CONDITION AGGRAVATED (Condition aggravated), DIARRHOEA (diarrhea), HEADACHE (Headache), ASTHENIA (Weakness), FATIGUE (Tiredness), NAUSEA (Nausea) and VOMITING (Vomiting) had not resolved.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 14-Mar-2021, COVID-19: negative (Negative) negative.         Patient received intravenous hydration and ibuprofen, acetaminophen, naproxen, ascorbic acid, air borne and oxymetazoline hydrochloride to help relieve symptoms in emergency room.  Based on the current available information and temporal association between the use of the product and the start date of these events, a causal relationship cannot be excluded.   Sender's Comments: Based on the current available information and temporal association between the use of the product and the start date of these events, a causal relationship cannot be excluded.
Diarrhea; Fever; Nausea; Vomiting; Based on the current case data, this case has been classified as invalid. This spontaneous case was reported by a nurse and describes the occurrence of DIARRHOEA (Diarrhea), PYREXIA (Fever), NAUSEA (Nausea) and VOMITING (Vomiting) in a patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     The patient's past medical history included No adverse reaction (no historical condition was reported).    On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced DIARRHOEA (Diarrhea), PYREXIA (Fever), NAUSEA (Nausea) and VOMITING (Vomiting). At the time of the report, DIARRHOEA (Diarrhea), PYREXIA (Fever), NAUSEA (Nausea) and VOMITING (Vomiting) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.
Passed out again; Patient broke her left hip; passed out; This spontaneous case was reported by a consumer and describes the occurrence of LOSS OF CONSCIOUSNESS (passed out), LOSS OF CONSCIOUSNESS (Passed out again) and HIP FRACTURE (Patient broke her left hip) in an 84-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 011A21A and 044H21H) for COVID-19 vaccination.     No Medical History information was reported.   On 24-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 24-Mar-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 08-Jun-2021, the patient experienced LOSS OF CONSCIOUSNESS (Passed out again) and HIP FRACTURE (Patient broke her left hip). In 2021, the patient experienced LOSS OF CONSCIOUSNESS (passed out). At the time of the report, LOSS OF CONSCIOUSNESS (passed out), LOSS OF CONSCIOUSNESS (Passed out again) and HIP FRACTURE (Patient broke her left hip) outcome was unknown.            In the last part of April or early May 2021, patient passed out and fell to the ground. On 08JUN2021, she passed out again, fell and broke her left hip. She was doing therapy now.  No concomitant medications were reported. No laboratory details were provided. No treatment medications were reported.  Very limited information regarding these events have been provided at this time. No further information is expected. Considering patient's advance age, no medical history provided and no clear temporal associotion between the reported events and vaccination casual relationship between the events and vaccine are considered unlikely related at this point in time.   Most recent FOLLOW-UP information incorporated above includes: On 07-Jul-2021: Live follow-up received contain no new information. Sender's Comments: Very limited information regarding these events have been provided at this time. No further information is expected. Considering patient's advance age, no medical history provided and no clear temporal associotion between the reported events and vaccination casual relationship between the events and vaccine are considered unlikely related at this point in time.
shoulder and muscle pain in the arm where injection was given. Started at 0230 on 3/11/12.  Injection was on 3/10/2021. No over the county meds taken. Does take Oxycodone prescribed from his dr. It helped some. No redness or swelling reported just aching pain.
Information has been received from a female consumer licensed practical nurse (L.P.N.), with allergies to cefaclor, morphine, DEMEROL, codeine, and TEQUIN and a history of herpes zoster through secondary exposure (WAES# 0611USA01550) who reported that a 1994, at approximately 41 years of age, had an unspecified reaction to PNEUMOVAX 23. No other information was available. It is also reported in WAES# 0709USA00291 that the patient experienced a local reaction which included a large, red inflamed area that was hot and painful and a rash from vaccination with a first dose of ZOSTAVAX (Oka/Merck) (lot# 658207/0883U) on 09-Aug-2007. Additional information has been requested.
pt resides in a residential facility; pt had a positive COVID test on 06/27/2022 in the facility; her condition deteriorated and she passed away in the facility.
7:30pm headache nausea vomiting muscle and joint pain red hard pone at injection site hot to touch site used ice on site took nausea medication lite diet and rest
PATIENT EXPERIENCED HIVES AND WAS SEEN AT AN URGENT TREATMENT CLINIC. PRESCRIBED STEROID ORAL AND TOPICAL. PT FOLLOWED UP WITH PCP WHO ALSO PRESCRIBED FURTHER STERIODS
Information has been received from a registered nurse concerning a 37-year-old white female employee who on 04/15/2002 was vaccinated SC in the left upper arm with a dose of measles virus vaccine live (+) mumps virus vaccine live (+) rubella virus vaccine live (second generation)(lot # 641459/0057M).  On 04/15/2002 the patient developed a fine red rash on her arms.  The patient's fine red rash on her arms has persisted.  The patient sought medical attention.  In follow-up the registered nurse reported that the patient's rash developed within an hour of receiving the vaccine, and that the patient's rash disappeared "within a few days".  No further information is expected.
Patient reported dizziness directly after receiving the shot, then describes an intense headache forming that has continued on and off for over a week including intermittent diarrhea.
This spontaneous report was received from Pfizer and was assigned manufacturer report # 2015220077 concerning a patient of unknown age and gender. On an unknown date, the patient was vaccinated with a dose of PNEUMOVAX 23 (dose, route and lot # not reported). Secondary suspect therapy included PREVNAR 13 (dose, route and lot # not reported) administered in April 2015. Concomitant therapies included and COUMADIN. "Recently", on an unknown date in 2015, the patient was hospitalized. The reason for hospitalization was unknown. There was also reported that the patient had a large bruise on the arm of injection. At the time of the report, the patient's outcome was unknown. This was originally reported by a pharmacist. Additional information has been requested.
Started experiencing numbness and other odd sensations in various body parts. Fatigue. Difficulty thinking clearly. Still experiencing now. Symptoms come and go.
On Dec 20th, i developed raised  hive rash that spread over body. I have had dermatographia since that day with instances of hives at times. It hasn't gone away yet.
Within 2 weeks of the first shot, patient developed acute joint pain in both hands and feet (digits - both). The pain was a 6-7 of 10 for the month of August every day, slowly abating to 5-6 in September, to 3-4 currently in November with fewer days of symptoms (every other day). Pain was most acute in finger knuckles with occasional manifestation in toe joints. No medication or pain relief used during this stretch of observation.
Physician reported today 01/07/2020 that patient seen today for left arm pain, complained of reaction worsening  and affecting her work. On exam she had a large 5x5cm tender mass in  posterior upper arm triceps area, consistent with possible  sterile abscess.  Ordered an ultrasound to be sure and the extent and to determine treatment if any.
Fever or Chills Fatigue  Headache  Sore throat  Congestion or running nose Cough  Nausea or vomiting
7 people had  died from Pfizer; This is a spontaneous report received from a non-contactable reporter(s) (Consumer or other non HCP).  An elderly (reported as "50-99" and "Age Group: Elderly (greater than equal to 65 years)") male patient received BNT162b2, BNT162b2 omi ba.4-5 (BNT162B2, BNT162B2 OMI BA.4-5), as dose number unknown, single (Batch/Lot number: unknown) for covid-19 immunization. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: DEATH (death), outcome "fatal", described as "7 people had  died from Pfizer". The date and cause of death for the patient were unknown. It was not reported if an autopsy was performed.  Clinical course: Age + years/months/days: 50-99. Age Group: Elderly (greater than equal to 65 years). Moderna has proven to be effective against COVID-19; Pfizer is not that effective when the reporter first heard about it. 7 people had died from Pfizer; So that made a change in mind about taking Moderna. Plus, the Primary Care doctor suggested Moderna based of these stories that the reporter heard. The reporter considers the event as caused by the suspect product.  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.; Sender's Comments: Linked Report(s) : US-PFIZER INC-PV202300139954 Same reporter/event/drug, different patient;; Reported Cause(s) of Death: 7 people had  died from Pfizer
bad pain in her heart area/it was so severe, she was "afraid to move". She "felt like her chest was going to split".; felt too weak to do anything else; This is a spontaneous report from a contactable consumer (patient). A female patient of an unspecified age (71; Units: Unknown) received BNT162B2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, solution for injection, Batch/Lot number was not reported), via an unspecified route of administration on 26Feb2021 as 1st dose, single for COVID-19 immunisation. The patient medical history and concomitant medications were not reported. On 01Mar2021 20:00, it was reported that, patient stated, received the first dose of the vaccine on 26Feb2021. She was expected to receive the second dose on 19Mar2021. She experienced a reaction after the first dose. Should she receive the second dose. The patient stated, the third night after receiving the first dose, at around 08:00PM, she started experiencing bad pain in her heart area. She says it was so severe, she was "afraid to move". She "felt like her chest was going to split". She felt too weak to do anything else. She added that it seemed like her heart was off beat. The patient underwent lab tests and procedures which included EKG: heart was in good shape on 2021. Outcome of all the events was an unknown.    No follow up attempts are possible, information about lot/batch number cannot be obtained.
High fever; This case was reported by a consumer and described the occurrence of fever in a adult patient who received Herpes zoster (Shingrix) for prophylaxis.   On 17th July 2019, the patient received the 1st dose of Shingrix. On 18th July 2019, 1 days after receiving Shingrix, the patient experienced fever. On an unknown date, the outcome of the fever was unknown.   It was unknown if the reporter considered the fever to be related to Shingrix.  Additional details were provided as follows: The age at vaccination was not reported. The age group was not reported, but was selected adult as per vaccine indication. The patient received Shingrix and the following day the patient experienced high fever. The customer ended the chat before gathering information and not able to gather demographics or adverse event questions.
VACCINE STORED AT OUTSIDE OF RECOMMENDED STORAGE CONDITION; VACCINE GIVEN OUTSIDE OF RECOMMENDED STORAGE CONDITION; This spontaneous report received from a physician concerned a 48 year old female. The patient's height, and weight were not reported. The patient's concurrent conditions included hypothyroidism, high blood pressure, diabetes, and sjogren's. The patient experienced drug allergy when treated with cefaclor, chlorhexidine, clindamycin, doxycycline, and sulfamethoxazole/trimethoprim. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, batch number: 202A21A expiry: 07-AUG-2021) dose was not reported, administered on 10-JUL-2021 for prophylactic vaccination. No concomitant medications were reported. On 10-JUL-2021, the subject experienced vaccine given outside of recommended storage condition. On an unspecified date, the subject experienced vaccine stored at outside of recommended storage condition. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The outcome of the vaccine given outside of recommended storage condition and vaccine stored at outside of recommended storage condition was not reported. This report was non-serious.
The day after receiving my second COVID test I developed chills, headache, and muscle/joint aching all over. This lasted for 2 days. No fever present.
1 day p/vax arm very sore & tender to touch-not swollen or red not better w/motrin;eval 9 days p/vax;told no serious pathology;
Fever & fussiness 1/3/11 - 1/6/11 extreme fussiness 1/6/11 x 24 hours rash - macular, blanchable 1/6/11 x 24 hours.
I just had a running nose. I had a temperature of 99.9. I had upper respiratory symptoms of congestion, wheezing and headache. I did a at home test, and I was positive for COVID-19. I had these symptoms a couple of days, then I contacted my doctor. They prescribed Paxlovid, I started feeling relief after a few days and soon after, I thought I was good for a while. The symptoms did return on 02/04/2023, I was testing positive still. I feel fine now, I still feel sluggish.
16 hours after vaccination developed severe muscle aches, chills and fever. The same symptoms I had when I had COVID infection (had COVID 3 weeks prior to Vaccination).
Aching all over; headaches; shingles; This is a spontaneous report from a contactable Nurse (Patient). A 56-year-old non-pregnant female patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 VACCINE, lot number: EJ1685) via an unspecified route of administration at right arm on 17Dec2020 13:00 at single dose for covid-19 immunization. The COVID-19 vaccine was administered at Hospital. Relevant medical history and concurrent conditions was reported as "Structured information (Patient episode name): Fibromyalgia, tachycardia, shingles, breast cancer". Patient was  diagnosed with COVID prior to vaccination. Patient known allergies included Codeine, morphine sulfate (Duramorph) and Sulfa. Concomitant medication included metoprolol succinate (TOPROL), alprazolam (XANAX) and desvenlafaxine succinate (PRISTIQ) received within 2 weeks of vaccination. No other vaccine in four weeks. Adverse events were reported as "Started day after shot. Aching all over headaches. Broke out in shingles 7 days later". Adverse event start date was reported on 24Dec2020. No treatment received for the events. since the vaccination, the patient was not been tested for COVID-19. The outcome of the events was recovering.
throat dryness and swelling; throat dryness; This is a spontaneous report from a contactable other healthcare professional. An adult female patient (reported as 38 and 28 years old) received first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, solution for injection, lot number number and expiry date: unknown) via an unspecified route of administration, on 23Dec2020, at a single dose, for Covid-19 immunization. The patient's medical history and concomitant medications were not reported. The patient received the first dose of the Covid-19 vaccine on 23Dec2020 and one hour afterwards she experienced throat dryness and swelling. She could still swallow but that the symptoms lasted about 45 minutes. Outcome of the events was unknown.  Information on the lot/batch number has been requested.